From June 16 to 18, 2026, the 24th World Pharmaceutical Raw Materials China Exhibition (CPHI China 2026) was grandly held at the Shanghai New International Expo Center. As an influential professional event in the global pharmaceutical industry, the total exhibition area of this exhibition exceeds 250000 square meters, with 36 exhibition halls, gathering more than 3700 exhibitors at home and abroad, and attracting more than 110000 professional visitors from more than 180 countries and regions. Shanghai Hengyuehe Biopharmaceutical Co., Ltd. (hereinafter referred to as "Hengyuehe") with one-stop CDMO service capabilities and core product matrix, with the global pharmaceutical colleagues to participate in the event.

deep cultivation of pharmaceutical research and development, full chain capability attracts attention

during the exhibition, hengyue he booth attracted a large number of domestic and foreign research and development, procurement decision-making levels to stop and negotiate. The company fully demonstrated its R & D and production strength in the fields of pharmaceutical intermediates, API (API), pharmaceutical excipients and high-end chemicals, focusing on the full-process CDMO service capability from laboratory trials to commercial mass production. As a high-tech enterprise established in 2010 and deeply cultivated in the industry for more than ten years, Hengyuehe can provide customers with a full range of services from new parent nuclear structure design, structure-effect relationship research, synthetic route process development to compound library synthesis, and deeply participate in all stages of customers' preclinical new drug research and development.

The company has a number of GMP-compliant production bases, equipped with a complete synthesis laboratory and quality testing center. With leading technology, strict quality control system and stable supply chain capabilities, Hengyue He has established long-term strategic cooperation with more than 120 well-known pharmaceutical companies at home and abroad.

CPHI platform enables accurate docking of global resources

CPHI China has been deeply involved in the industry for more than 20 years and is the core platform for domestic pharmaceutical enterprises to dock global upstream and downstream resources. This exhibition brought together pavilions from 33 countries and regions, linking the supply chain resources of more than 180 countries around the world. Overseas pre-registration audiences increased by more than 20% year-on-year, and cooperation and transformation achieved outstanding results. With the help of this international platform, Hengyuehe has conducted in-depth discussions with pharmaceutical companies and purchasers from Europe, Southeast Asia, the Middle East and other regions, and reached a number of preliminary cooperation intentions on API supply and CDMO project cooperation.

During the exhibition, the company team also had extensive exchanges with industry colleagues on cutting-edge issues such as green synthesis technology and the development of high value-added intermediates. As the global pharmaceutical industry moves from "scale competition" to "technology density", Hengyue Wo's technology accumulation in process optimization, impurity control and large-scale production has been highly recognized by visiting customers.

to promote the industry, continue to deepen the global layout

CPHI China 2026 has come to a successful conclusion, but hengyue he link the world, the pace of service innovation will not stop. The company will continue to rely on international exhibition platforms such as CPHI, continue to expand overseas market channels, and deepen cooperation with global pharmaceutical companies, biotechnology companies and scientific research institutions.

In the future, Shanghai Hengyuehe Biopharmaceutical Co., Ltd. will continue to uphold the concept of innovation-driven development, with excellent research and development strength, strict quality standards and stable supply chain capabilities, to provide global customers with higher quality Pharmaceutical raw materials and customized CDMO services, and jointly empower the new journey of pharmaceutical research and development.